MAPT and Alzheimer disease: The present study identified an association between a panel of blood miRNAs and the ratio of P-tau/Aβ42 in the CSF of patients with AD, suggesting miRNAs as a promising tool for predicting the Aβ42 and P-tau levels in patients with AD.